08.09.2020 12:51:17
|
Pre-market Movers In Healthcare Sector: ALBO, BIOC, KMDA, BNTX…
(RTTNews) - What's moving these stocks in the pre-market hours today?
In the Green
1. Biocept Inc. (BIOC) is up over 800% at $4.97 in pre-market trading Tuesday as the company's stock is all set to begin trading on a 1-for-10 reverse stock split basis today.
2. Kamada Ltd. (KMDA) is up over 10% at $9.70 in pre-market trading Tuesday. The company's investigational COVID-19 treatment, a plasma-derived hyperimmune IgG therapy, is under a phase I/II trial in Israel.
3. Albireo Pharma Inc. (ALBO) is up over 68% at $46 in pre-market hours Tuesday as the company awaits topline results from its PEDFIC 1 phase III clinical trial today. PEDFIC 1 is evaluating the efficacy and safety of lead candidate Odevixibat for the treatment of progressive familial intrahepatic cholestasis.
4. Corbus Pharmaceuticals Holdings Inc. (CRBP) is up 9% at $1.10 in pre-market trading Tuesday. The company is slated to report topline data from a phase III study of Lenabasum for treatment of systemic sclerosis, dubbed RESOLVE-1 and results from a phase IIb study of Lenabasum in cystic fibrosis this month.
5. BioNTech SE (BNTX) is up more than 7% at $62.91 in pre-market hours today. The company received clearance from the German regulatory authority yesterday to begin a Phase 2/3 clinical trial of BNT162b2 vaccine candidate for COVID-19 in Germany. The vaccine is being developed in partnership with Pfizer.
In the Red
1. Seelos Therapeutics Inc. (SEEL) is down more than 6% at $0.55 in pre-market hours today, adding to Friday's loss of over 28%. On Friday, the company announced the pricing of a $7.0 million registered direct offering. The registered direct offering and concurrent private placement are expected to close on or about September 9, 2020.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu BioNTech (ADRs)mehr Nachrichten
02.12.24 |
BioNTech-Aktie dennoch in Rot: Kein Erfolg bei Klage wegen Impfschäden (dpa-AFX) | |
26.11.24 |
BioNTech-Aktie tiefer: JPMorgan hat Ziel für BioNTech reduziert (dpa-AFX) | |
26.11.24 |
ANALYSE-FLASH: Goldman belässt Biontech auf 'Buy' - Ziel 137 Dollar (dpa-AFX) | |
20.11.24 |
BioNTech-Aktie auf Erholungskurs: Analysten loben BioNTech und sehen deutliches Aufwärtspotenzial (finanzen.at) | |
18.11.24 |
ANALYSE-FLASH: Goldman belässt Biontech auf 'Buy' - Ziel 137 Dollar (dpa-AFX) | |
15.11.24 |
Impfstoffwerte wie BioNTech unter Druck - Trump nominiert Skeptiker (dpa-AFX) | |
13.11.24 |
Biontech übernimmt chinesische Biotechnologie-Firma (dpa-AFX) | |
13.11.24 |
BioNTech strikes $950mn deal for Chinese drugmaker Biotheus (Financial Times) |
Analysen zu BioNTech (ADRs)mehr Analysen
17.12.24 | BioNTech Neutral | JP Morgan Chase & Co. | |
12.12.24 | BioNTech Buy | Jefferies & Company Inc. | |
11.12.24 | BioNTech Neutral | JP Morgan Chase & Co. | |
27.11.24 | BioNTech Buy | Deutsche Bank AG | |
26.11.24 | BioNTech Buy | Goldman Sachs Group Inc. |